Flexible supply chains, investments in greener technology, and health care accessibility in the statement from CEO Paolo Tuberini

    In an exclusive interview, Olon’s CEO Paolo Tuberini discussed of the future of the group, and all the changes and processes ongoing due to the Covid-19 pandemic: a whole new awareness that involves supply chains, technology investments and health care accessibility.

    The industry is increasingly considering dual-sourcing key materials and APIs to ensure supply chains are not hindered, even on the occasion of exceptional and unexpected events in a specific area of the world. Olon was prepared for this, putting in place a business continuity program that requires diversified sources for all the key raw materials. To reinforce this risk mitigation plan, the sourcing strategy requires that each of these sources is based in a different geographic area than the first source.

    Olon announced an investment of €27m, solely on the expansion of further internal expertise and capacity of high containment production throughout 2022 and 2023, and the completion of a new large-scale high containment production line (OEL < 1 ug/m3) at the Rodano site, worth around €10m. This will enable Olon to produce highly potent APIs (HPAPIs) in large-scale product batches ranging from 30kg to 250kg, serving the customer along all the stages of scale-up.

    The constant evolution of active ingredients, especially in complex fields such as oncology, requires highly specific technologies, systems, and skills to meet the standard of containment procedures, guaranteeing the prevention of exposure to the operators and contamination of the products.

    Olon has invested in microbial fermentation capabilities, a recombinant DNA technology that can be applied to manufacturing life-saving treatments, to improve synthesis procedures with greener methods, that significantly reduce the use of chemical solvents and the costs of production, integrating the two areas of chemistry and biotechnology.

    This process means laboratory-created enzymes can transform a given starting material into the desired finished product by using water at room temperature, without requiring special technologies that require significant amounts of energy, virtually eliminates the use of solvents and toxic reagents, responding perfectly to sustainability targets.

    There is also a movement to launch large-scale biocatalysis as an industrial technology to improve sustainability, spearheaded by Olon, with an international network that brings together experts in the field from both industry and academia to pioneer its usage for greener chemical reactions.

    Fellow members include the Biocatalysis Group of the Van’t Hoff Institute for Molecular Sciences (HIMS-Biocat) of the University of Amsterdam and Biosphere. an Italian small-medium enterprise that specializes in fermentation and industrial biotechnology. While sustainability is critical for the future of patients, the life sciences industry remains committed to making changes that also ensure medicine access for patients.

    Olon’s manufacturing expertise has enabled it to create better, more sustainable processes without compromising on efficiency of generics production. In addition, having the capacity and expertise to support pharma and biotech companies in bringing new medicines to market means Olon is committed to the next generation of treatments. 

    Read more on Olon Group website > Flexible supply chains, investments in greener technology, health care accessibility